TSX:CORV

Stock Analysis Report

Executive Summary

Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide.

Snowflake

Fundamentals

High growth potential with weak fundamentals.


Similar Companies

Share Price & News

How has Correvio Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.0%

CORV

-9.2%

CA Pharmaceuticals

-0.1%

CA Market


1 Year Return

-46.9%

CORV

-60.2%

CA Pharmaceuticals

0.9%

CA Market

Return vs Industry: CORV exceeded the Canadian Pharmaceuticals industry which returned -60.2% over the past year.

Return vs Market: CORV underperformed the Canadian Market which returned 0.9% over the past year.


Shareholder returns

CORVIndustryMarket
7 Day-3.0%-9.2%-0.1%
30 Day-38.2%-26.9%-2.1%
90 Day-9.3%-37.2%-1.6%
1 Year-46.9%-46.9%-60.2%-60.2%4.4%0.9%
3 Year-43.0%-43.0%77.3%76.0%15.5%5.2%
5 Year-73.9%-73.9%266.3%266.3%25.7%7.5%

Price Volatility Vs. Market

How volatile is Correvio Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Correvio Pharma undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Correvio Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Correvio Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Correvio Pharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

70.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CORV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: CORV is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: CORV's loss is forecast to worsen by 0% next year.

Revenue vs Market: CORV's revenue (32.1% per year) is forecast to grow faster than the Canadian market (5.7% per year).

High Growth Revenue: CORV's revenue (32.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if CORV's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Correvio Pharma performed over the past 5 years?

-4.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CORV is unprofitable, and losses have increased over the past 5 years at a rate of -4.2% per year.

Accelerating Growth: Unable to compare CORV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CORV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).


Return on Equity

High ROE: CORV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: CORV is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CORV is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Correvio Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: CORV has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CORV has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CORV has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CORV's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: CORV has a low level of unsold assets or inventory.

Debt Coverage by Assets: CORV has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CORV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CORV has less than a year of cash runway if free cash flow continues to reduce at historical rates of -3.1% each year


Next Steps

Dividend

What is Correvio Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CORV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CORV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CORV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CORV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CORV's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Correvio Pharma's salary, the management and board of directors tenure and is there insider trading?

2.7yrs

Average management tenure


CEO

Mark H. Corrigan (61yo)

0.6yrs

Tenure

US$273,697

Compensation

Dr. Mark H. N. Corrigan, M.D., serves as Independent Director of Wave Life Sciences Ltd. since September 4, 2019. Dr. Corrigan is Lead Independent Director of Blackthorn Therapeutics, Inc. since November 5 ...


Management Age and Tenure

2.7yrs

Average Tenure

58yo

Average Age

Experienced Management: CORV's management team is considered experienced (2.7 years average tenure).


Board Age and Tenure

4.3yrs

Average Tenure

61yo

Average Age

Experienced Board: CORV's board of directors are considered experienced (4.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$58,40416 Jan 19
Justin Renz
EntityIndividual
Role
President
CFO & President
Shares20,000
Max PriceUS$2.92

Ownership Breakdown


Management Team

  • Sheila Grant

    Chief Operating Officer

    • Tenure: 6.6yrs
    • Compensation: US$700.34k
  • Bill Hunter (56yo)

    Director

    • Tenure: 12.3yrs
    • Compensation: US$1.82m
  • David McMasters (60yo)

    General Counsel

    • Tenure: 6.9yrs
    • Compensation: US$709.76k
  • Mark H. Corrigan (61yo)

    CEO & Director

    • Tenure: 0.6yrs
    • Compensation: US$273.70k
  • David Dean

    Chief Business Development Officer

    • Tenure: 2.4yrs
  • Justin Renz (47yo)

    CFO & President

    • Tenure: 0.8yrs
    • Compensation: US$886.18k
  • Hugues Sachot

    Chief Commercial Officer

    • Tenure: 3yrs
    • Compensation: US$800.49k

Board Members

  • Bill Hunter (56yo)

    Director

    • Tenure: 12.3yrs
    • Compensation: US$1.82m
  • Richard Glickman (61yo)

    Director

    • Tenure: 12.8yrs
    • Compensation: US$171.28k
  • Mark H. Corrigan (61yo)

    CEO & Director

    • Tenure: 0.6yrs
    • Compensation: US$273.70k
  • Jim O'Shea (69yo)

    Chairman

    • Tenure: 4.3yrs
    • Compensation: US$202.83k
  • Vanda De Cian

    Director

    • Tenure: 0.6yrs
  • Arthur Willms

    Director

    • Tenure: 4.3yrs
    • Compensation: US$158.32k
  • Robert Meyer (61yo)

    Director

    • Tenure: 4.1yrs
    • Compensation: US$142.83k

Company Information

Correvio Pharma Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Correvio Pharma Corp.
  • Ticker: CORV
  • Exchange: TSX
  • Founded: 2018
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$113.638m
  • Shares outstanding: 50.51m
  • Website: https://www.correvio.com

Number of Employees


Location

  • Correvio Pharma Corp.
  • 1441 Creekside Drive
  • 6th Floor
  • Vancouver
  • British Columbia
  • V6J 4S7
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CORVTSX (The Toronto Stock Exchange)YesCommon SharesCACADJan 1990
CORVNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJan 1990
72RDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1990

Biography

Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acut ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 23:33
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.